Skip to main content

Table 4 Most frequent reasons for drop out across global regions a

From: Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

Study program Treatment group North America Western Europe Australia/South Africa Japan Asia Eastern Europe/Russia South America/Mexico
IDENTITY Placebo 1. AEs = 43 (48%) 1. AEs = 19 (51%) 1. CG decision = 4 (44%) 1. AEs = 4 (36%) 1. Participant decision = 9 (45%) 1. Participant decision = 32 (59%) 1. Participant decision = 6 (38%)
2. Participant decision = 15 (17%) 2. Participant decision = 9 (24%) 1. Participant decision = 4 (44%) 2. CG decision = 3 (27%) 2. AEs = 6 (30%) 2. AEs = 15 (28%) 2. CG decision = 3 (19%)
2. Death = 3 (27%) 2. AEs = 3 (19%)
Semagacestat 140 mg PO 1. AEs = 105 (55%) 1. AEs = 55 (66%) 1. AEs = 12 (48%) 1. AEs = 28 (74%) 1. AEs = 18 (47%) 1. AEs = 33 (46%) 1. AEs = 25 (49%)
2. Participant decision = 38 (20%) 2. Participant decision = 12 (14%) 2. Death = 5 (20%) 2. CG decision = 6 (16%) 2. Participant decision = 13 (34%) 2. Participant decision = 12 (42%) 2. Participant decision = 13 (25%)
EXPEDITION Placebo 1. AEs = 39 (31%) 1. AEs = 19 (38%) 1. AEs = 3 (50%) 1. AEs = 5 (50%) 1. Participant decision = 4 (36%) 1. Participant decision = 9 (38%) 1. Participant decision = 10 (36%)
2. CG decision = 33 (26%) 2. Participant decision = 14 (28%) 2. CG decision = 1 (17%) 2. Participant decision = 2 (20%) 2. AEs = 2 (18%) 2. AEs = 5 (21%) 2. AEs = 7 (25%)
2. Physician decision = 1 (17%) 2. Death = 2 (18%)
2. Death = 1 (17%)
Solanezumab 400 mg IV 1. CG decision = 39 (27%) 1. AEs = 16 (38%) 1. AEs = 7 (64%) 1. AEs = 5 (45%) 1. AEs = 2 (25%) 1. CG decision = 6 (43%) 1. Participant decision = 6 (29%)
2. AEs = 34 (24%) 2. Participant decision = 10 (24%) 2. Participant decision = 2 (18%) 2. CG decision = 4 (36%) 1. Participant decision = 2 (25%) 2. AEs = 3 (21%) 2. AEs = 5 (24%)
2. Physician decision = 2 (18%) 1. Protocol violation = 2 (25%) 2. Participant decision = 3 (21%)
  1. aData are presented as count (%). AE = Adverse event; CG = Caregiver; IV = Intravenously; PO = By mouth.